One Step Forward, Two Steps Back
By Osagie Obasogie,
San Francisco Chronicle
| 07. 05. 2005
NitroMed's BiDil recently received FDA approval as the first drug targeted exclusively for a racial group -- African Americans with heart failure. Although this condition affects Americans by the hundreds of thousands, BiDil's label will effectively read that Whites, Latinos, East and South Asians and folks from the Middle East need not buy; only those whom society considers "black" -- a concept as slippery as pinpointing the race of Michael Jackson, Soledad O'Brien or Mariah Carey -- should take this drug.
Does this make sense? Is this good science? BiDil has been met with both celebration and admonition. Many scientists see this as the pharmaceutical man landing on the genomic moon -- a bold first step to a future where medications are developed specifically for individuals' biochemical predispositions. A number of black physicians are joining NitroMed shareholders' jubilations. Charles L. Curry, president of the International Society on Hypertension in Blacks, told the Washington Post that BiDil is "the most significant advance in the treatment of black people that [he had] seen in [his] lifetime." So much for penicillin.
At the...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...